Recordati SpA (Recordati SpA) Dividend Payout Ratio : 1.41 (As of Dec. 2023)

View and export this data going back to 2010. Start your Free Trial

What is Recordati SpA Dividend Payout Ratio?

Recordati SpA's dividend payout ratio for the months ended in Dec. 2023 was 1.41.

The historical rank and industry rank for Recordati SpA's Dividend Payout Ratio or its related term are showing as below:

RCDTF' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.47 Med: 0.56 Max: 0.65
Current: 0.63

During the past 13 years, the highest Dividend Payout Ratio of Recordati SpA was 0.65. The lowest was 0.47. And the median was 0.56.

RCDTF's Dividend Payout Ratio is ranked worse than
78.69% of 427 companies
in the Drug Manufacturers industry
Industry Median: 0.33 vs RCDTF: 0.63

As of today (2024-05-25), the Dividend Yield % of Recordati SpA is 0.00%.

During the past 13 years, the highest Trailing Annual Dividend Yield of Recordati SpA was 3.71%. The lowest was 1.72%. And the median was 2.40%.

Recordati SpA's Dividends per Share for the months ended in Dec. 2023 was $0.62.

During the past 12 months, Recordati SpA's average Dividends Per Share Growth Rate was 4.50% per year. During the past 3 years, the average Dividends Per Share Growth Rate was 4.70% per year. During the past 5 years, the average Dividends Per Share Growth Rate was 5.80% per year. During the past 10 years, the average Dividends Per Share Growth Rate was 13.70% per year.

During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of Recordati SpA was 30.20% per year. The lowest was -8.00% per year. And the median was 13.60% per year.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Recordati SpA Dividend Payout Ratio Historical Data

The historical data trend for Recordati SpA's Dividend Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Recordati SpA Dividend Payout Ratio Chart

Recordati SpA Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dividend Payout Ratio

Get a 7-Day Free Trial

0.53

0.59

0.56

0.65

0.63

Recordati SpA Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Dividend Payout Ratio	Get a 7-Day Free Trial															-	1.20	-	1.41	-

Competitive Comparison of Recordati SpA's Dividend Payout Ratio

For the Drug Manufacturers - General subindustry, Recordati SpA's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Recordati SpA's Dividend Payout Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Recordati SpA's Dividend Payout Ratio distribution charts can be found below:

* The bar in red indicates where Recordati SpA's Dividend Payout Ratio falls into.

Recordati SpA Dividend Payout Ratio Calculation

Dividend payout ratio measures the percentage of the company's earnings paid out as dividends.

Recordati SpA's Dividend Payout Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (A: Dec. 2023 )	/	EPS without NRI (A: Dec. 2023 )
	=	1.276	/	2.029
	=	0.63

Recordati SpA's Dividend Payout Ratio for the quarter that ended in Dec. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Dec. 2023 )	/	EPS without NRI (Q: Dec. 2023 )
	=	0.622	/	0.442
	=	1.41

Recordati SpA (OTCPK:RCDTF) Dividend Payout Ratio Explanation

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

Recordati SpA Dividend Payout Ratio Related Terms

Thank you for viewing the detailed overview of Recordati SpA's Dividend Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Recordati SpA (Recordati SpA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Recordati SpA (OTCPK:RCDTF) » Definitions » Dividend Payout Ratio

Comparable Companies

Traded in Other Exchanges

RICFY:USA REC:Italy RECm:UK 0KBS:UK RER1:Germany

Address

Via Matteo Civitali 1, MIlan, ITA, 20148

Website

https://www.recordati.com

Recordati SpA is a drug manufacturing company that focuses on specialty pharmaceuticals. The company produces and promotes medicines globally that focus on primary-care therapies and rare diseases. Recordati uses strategic partnerships as part of its long-term growth. The vast majority of the company's revenue is generated in Italy, followed by the United States, France, and Germany. Recordati reports two operating segments: Specialty and Primary care and Rare diseases. The bulk of the company's profit is derived from its specialty and primary care segment, which includes the production of active ingredients.

Recordati SpA (Recordati SpA) Headlines

From GuruFocus

Recordati Rare Diseases Announces First European Launch of Isturisa® (osilodrostat)

By Business Wire Business Wire • 06-02-2020

Isturisa® Is Now Available as a Medical Treatment for Cushing's Syndrome in Germany

By Business Wire Business Wire • 07-16-2020

Recordati Rare Diseases Announce Publication of Long-term Outcomes From the Extension to the Phase III LINC 3 Study of Isturisa� (Osilodrostat) in Patients With Cushing's Disease in the European Journal of Endocrinology

By Business Wire Business Wire • 08-31-2022

Recordati: Isturisa® (Osilodrostat) Approved In The U.S.

By PRNewswire PRNewswire • 03-09-2020

ARS Pharmaceuticals and Recordati Announce Exclusive License for the Rights in Europe and additional countries for Neffy� (ARS-1; epinephrine nasal spray)

By PRNewswire PRNewswire • 09-22-2020

Recordati: Positive Results From the Phase III LINC-3 Study of Isturisa® (osilodrostat) for the Treatment of Cushing's Disease Published in Lancet Diabetes & Endocrinology

By Business Wire Business Wire • 07-28-2020

Recordati Rare Diseases: Isturisa® (osilodrostat) Phase III LINC-4 Trial Meets Its Primary Endpoint in Cushing's Disease

By Business Wire Business Wire • 06-17-2020

Recordati Rare Diseases Announce Publication in the Journal of Clinical Endocrinology & Metabolism of the Phase III LINC 4 Study Confirming the Efficacy and Safety of Isturisa� (Osilodrostat) in Patients With Cushing's Disease

By Business Wire Business Wire • 03-29-2022